ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Kazia Therapeutics Ltd

Kazia Therapeutics Ltd (KZIA)

0.7113
0.139
( 24.29% )
Updated: 04:41:01

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.7113
Bid
0.7028
Offer
0.7113
Volume
17,386,567
0.535 Day's Range 0.75
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.5723
Open
0.56
Last Trade
100
@
0.7113
Last Trade Time
04:41:01
Financial Volume
US$ 10,915,968
VWAP
0.627839
Average Volume (3m)
-
Shares Outstanding
22,802,911
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Kazia Therapeutics Ltd

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Sydney, New South Wales, Aus
Founded
1970
Kazia Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KZIA. The last closing price for Kazia Therapeutics was US$0.57. Over the last year, Kazia Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Kazia Therapeutics currently has 22,802,911 shares in issue. The market capitalisation of Kazia Therapeutics is US$13.05 million.

KZIA Latest News

Biotech Experiences Strong Open Following Major Announcement

An Australian biotech company is already turning heads so far on Wednesday after it was announced results from its GBM-AGILE, which is a phase II/III study that included an To read the full story...

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma PR Newswire SYDNEY, July 10, 2024 GBM AGILE trial data shows clinically meaningful improvement in a...

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER PR Newswire SYDNEY, June 27, 2024 SYDNEY, June 27, 2024 /PRNewswire/ -- Kazia Therapeutics...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMBCambium Bio Ltd
AUD 0.40
(9,900.00%)
2k
LRLLabyrinth Resources Ltd
AUD 0.015
(200.00%)
42.23M
VPRVolt Group Ltd
AUD 0.002
(100.00%)
343.18k
TD1Tali Digital Limited
AUD 0.0015
(50.00%)
10k
PRXProdigy Gold NL
AUD 0.003
(50.00%)
1.47M
RHYORhythm Biosciences Limited
AUD 0.005
(-75.00%)
916
JTLJayex Technology Limited
AUD 0.001
(-50.00%)
1.34M
EDEEden Innovations Ltd
AUD 0.001
(-50.00%)
79k
DTIDTI Group Limited
AUD 0.009
(-35.71%)
4.16k
SI6Si6 Metals Limited
AUD 0.002
(-33.33%)
2.8M
ATHAlterity Therapeutics Ltd
AUD 0.007
(40.00%)
154.34M
AMDArrow Minerals Limited
AUD 0.003
(20.00%)
123.6M
FBRFBR Limited
AUD 0.05
(4.17%)
64.55M
MRQOMRG Metals Limited
AUD 0.001
(0.00%)
43.5M
LRLLabyrinth Resources Ltd
AUD 0.015
(200.00%)
42.23M

KZIA Discussion

View Posts
Hercules1 Hercules1 2 hours ago
$1 break is close.
πŸ‘οΈ0
Hercules1 Hercules1 1 day ago
Buying is picking up
πŸ‘οΈ0
Hercules1 Hercules1 1 day ago
.70 close is a good possibility.

Grabbed a few more.
πŸ‘οΈ0
XenaLives XenaLives 1 day ago
More charts... se replied to for long term chart.



πŸ‘οΈ0
trendzone trendzone 2 days ago
Heading back below $0.50 the sellers of the $0.50 puts morons served on a half shell
πŸ‘οΈ0
LionsPride LionsPride 5 days ago
credentials still work hadnt been here in a few years
πŸ‘οΈ0
LionsPride LionsPride 5 days ago
interesting volume 3rd leg next week hmmmm
πŸ‘οΈ0
GhosTraderX GhosTraderX 6 days ago
After Hours trading looking Good...

Should open above 1.50 at 9:30am...

Bought the Dip at 1.00 average...

GhosT
πŸ‘οΈ0
BurgerKing82 BurgerKing82 6 days ago
Is it too high to buy....Volume was good...Has seemed to Wane a bit...
πŸ‘οΈ0
BurgerKing82 BurgerKing82 6 days ago
Good Call Ghost...This thing ran from 20 to 160 in a couple days...wow...I remember seeing it at 30...
πŸ‘οΈ0
GhosTraderX GhosTraderX 6 days ago
Closed my Position at 1.45 average...

On watch for now...

GhosT
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 6 days ago
TOP IN AGAIN
πŸ‘οΈ0
subslover subslover 6 days ago
Thank you Tommyboy🥰
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 6 days ago
$KZIA
$KZIA Highlighted the break over the 200 day MA yesterday during trading..pointed out how much room it had to run..just over $1 now Premarket..In pure beast mode now.. let’s see if it can get through the residence between $1-$1.15.. pic.twitter.com/YHRJarumZR— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) July 11, 2024
👍️ 1
subslover subslover 6 days ago
If you can stomach the volatility then you will be just fine!
πŸ‘οΈ0
maq1214 maq1214 6 days ago
Yes indeed ! Have they applied for FDA
πŸ‘οΈ0
subslover subslover 6 days ago
I feel you have to go with Xena's chart in the long term. The News yesterday was huge and moving forward if this passes phase 3 FDA approval a major pharmaceutical Company will buy it out!
πŸ‘οΈ0
maq1214 maq1214 6 days ago
Hi all. im new here. The explosion yesterday brought me to this stock. Am I late or has this got the potential to break over a dollar. thanks
πŸ‘οΈ0
XenaLives XenaLives 6 days ago
Intriguing long term chart...



another chart:

👍️ 1
TrendTrade2016 TrendTrade2016 6 days ago
algo trap
πŸ‘οΈ0
Zardiw Zardiw 7 days ago
$KZIA +248% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z
πŸ‘οΈ0
Invest-in-America Invest-in-America 7 days ago
KZIA: My BAD!!! ("Finviz", below, says YOU are correct!!)
https://finviz.com/quote.ashx?t=KZIA&p=d
Google, below, mislead me:
https://www.google.com/search?q=kzia+stock+float&sca_esv=54722a0b5ffac30e&sca_upv=1&source=lnms&sa=X&ved=2ahUKEwjyta_75Z2HAxWIBe8CHd5GABEQ0pQJegQIBRAC&biw=1366&bih=657&dpr=1
πŸ‘οΈ0
Cuppy Cuppy 7 days ago
The outstanding shares are only about 23,000,000:
https://www.otcmarkets.com/stock/KZIA/security
πŸ‘οΈ0
subslover subslover 7 days ago
Nice strong A.H. close at .95 :)
πŸ‘οΈ0
GhosTraderX GhosTraderX 7 days ago
After Hours trading looking good...

Should open above 1.00 at 9:30am...

Bought the Dip 0.58 average...

GhosT
πŸ‘οΈ0
Invest-in-America Invest-in-America 7 days ago
KZIA: 243-million Float, & yet soared like that??? (O.K., so there goes the old "Small-Float" theory.)
👍️ 1
glenn1919 glenn1919 1 week ago
KZIA........................................https://stockcharts.com/h-sc/ui?s=KZIA&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
madras50 madras50 1 week ago
yeah, mine wasn't top of cloud but .40 to .82 not bad i guess
πŸ‘οΈ0
KOmani KOmani 1 week ago
One of the drugs with the Standard of care for glioblastoma is Temodar.

Temodar had sales of $800 million in 2022.

Hmmm .... makes this stock with a market cap of less than $30 million look interesting?

We shall see, but it looks good....
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
NO...TOP OF CLOUD EXIT
πŸ‘οΈ0
madras50 madras50 1 week ago
you still holding?
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
WOW YOU ARE GOOD...CALLING HALTS DOES NOT MAKE $$$
πŸ‘οΈ0
Awl416 Awl416 1 week ago
About to halt
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...DOLLA BREAK
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...TOP WEEKLY CLOUD TEST COMING UP
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
HERE WE GO TO A DOLLA
πŸ‘οΈ0
Adam16 Adam16 1 week ago
Why don’t I ever get lucky like this? Smh
πŸ‘οΈ0
subslover subslover 1 week ago
Let's get back over $1.00 and b become compliant again :)
πŸ‘οΈ0
Awl416 Awl416 1 week ago
Crazy
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...78C HALT....LETS SEE A DOLLAR
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...HERE WE GO TO 77C
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...77C MAGNET UP AHEAD
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA HERE WE GO ...NEW HIGH BREAK
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...HERE WE GO
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA HERE WE GO
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 week ago
KZIA...ON THE MOVE PHASE 3 RESULTS
πŸ‘οΈ0
subslover subslover 1 week ago
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma

SYDNEY, July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics.


GBM AGILE STUDY
GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GCAR), a nonprofit organization comprised of some of the world's foremost clinical, translational, and basic science researchers, from institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. The trial is designed to efficiently screen for and characterize the response of glioblastoma (GBM) patients to novel investigative agents. Utilizing a complex innovative design, Bayesian principles are applied to the primary endpoint (Overall Survival) comparison of the investigational agents to patients receiving Standard of Care (SOC) enrolled from the study start (also referred to as cumulative control population). In general, secondary analyses and endpoints are assessed based on established statistical models in comparison to the control patients enrolled at the same time as the investigational agent (concurrent control population).

Paxalisib is the third drug candidate to complete its evaluation in the study and was evaluated in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status as well as in patients with recurrent disease.

GBM AGILE Paxalisib Results

Kazia CEO, Dr John Friend stated, "We are excited to have shown a 3.8 month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult to treat glioblastoma population. We look forward to discussing possible approaches for an accelerated approval pathway for paxalisib with the FDA."

A total of 313 newly diagnosed unmethylated (NDU) patients and recurrent patients being treated at top US cancer hospitals were randomized in Stage 1 to either a paxalisib treatment arm (60 mg/day) or the SOC concurrent control arm from January 2021 to May 2022. The cumulative control arm was enrolled from July 2019 (GBM Agile study start date) to May 2022.

For the primary analysis the median Overall Survival (OS) was 14.77 months for paxalisib-treated NDU patients (n=54) versus 13.84 months for cumulative SOC NDU patients (n=75).

For a prespecified secondary analysis in the NDU patients, median OS was 15.54 months in the paxalisib arm (n=54) versus 11.89 months for concurrent SOC (n=46). In addition, a prespecified sensitivity analysis in NDU patients showed similar median OS difference between paxalisib treated patients (15.54 months) and concurrent SOC patients (11.70 months).

The secondary analysis results are consistent with the previously reported Company-sponsored phase II study, where median OS was 15.7 months (n=27) for paxalisib treated NDU patients compared to 12.7 months historically reported with temozolomide in this patient group (Wen 2022).

Paxalisib was well tolerated in GBM-AGILE, and no new safety signals were identified in this patient population.

An efficacy signal was not detected in the recurrent disease population (median OS of 9.69 months for concurrent SOC (n=113) versus 8.05 months for paxalisib (n=100). Similar results in this population have been reported in the other two drug candidates that have completed the GBM AGILE trial. Kazia is currently pursuing further analyses of this data to elucidate potential signals for further consideration.

Based on the totality of data available from all completed paxalisib clinical studies in newly diagnosed unmethylated GBM patients, Kazia will request a meeting with the US Food & Drug Administration (FDA) to discuss the results and determine if a potential path to accelerated approval is appropriate for paxalisib.

Paxalisib has previously received orphan drug designation and fast track designation from the FDA for glioblastoma in unmethylated MGMT promoter status patients, following radiation plus temozolomide therapy.

Full data including secondary endpoints from the paxalisib arm of the GBM AGILE study is expected to be presented at a scientific meeting later this year.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, has been completed with presentation of paxalisib arm data expected later in 2024 at a major medical conference. Other clinical trials involving paxalisib are
πŸ‘οΈ0
glenn1919 glenn1919 1 week ago
KZIA...........................................https://stockcharts.com/h-sc/ui?s=KZIA&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
powerbattles powerbattles 3 months ago
.40 breakout that is sweet $$
πŸ‘οΈ0
powerbattles powerbattles 3 months ago
Slowly win the race $$$
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock